These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 22459724)

  • 1. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial.
    Knorr U; Vinberg M; Mortensen EL; Winkel P; Gluud C; Wetterslev J; Gether U; Kessing LV
    PLoS One; 2012; 7(2):e31980. PubMed ID: 22393376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram and neuroendocrine response in healthy first-degree relatives to depressed patients--a randomized placebo-controlled trial.
    Knorr U; Vinberg M; Hansen A; Klose M; Feldt-Rasmussen U; Hilsted L; Hasselstrøm J; Gether U; Winkel P; Gluud C; Wetterslev J; Kessing LV
    PLoS One; 2011; 6(6):e21224. PubMed ID: 21738622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial.
    Knorr U; Koefoed P; Gluud C; Wetterslev J; Winkel P; Gether U; Vinberg M; Kessing LV
    Nord J Psychiatry; 2016; 70(4):297-302. PubMed ID: 26752119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression.
    Knorr U; Vinberg M; Klose M; Feldt-Rasmussen U; Hilsted L; Gade A; Haastrup E; Paulson O; Wetterslev J; Gluud C; Gether U; Kessing L
    Trials; 2009 Aug; 10():66. PubMed ID: 19671139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression.
    Knorr U; Vinberg M; Gade A; Winkel P; Gluud C; Wetterslev J; Gether U; Kessing L
    Ther Adv Psychopharmacol; 2011 Oct; 1(5):133-44. PubMed ID: 23983938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
    Knorr U; Vinberg M; Gether U; Winkel P; Gluud C; Wetterslev J; Kessing LV
    Psychiatry Res; 2012 Dec; 200(2-3):354-60. PubMed ID: 22703642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personality change during depression treatment: a placebo-controlled trial.
    Tang TZ; DeRubeis RJ; Hollon SD; Amsterdam J; Shelton R; Schalet B
    Arch Gen Psychiatry; 2009 Dec; 66(12):1322-30. PubMed ID: 19996037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
    Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
    Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
    Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
    Weber S; Frokjaer VG; Armand S; Nielsen JH; Knudsen GM; Joergensen MB; Stenbaek DS; Giraldi A
    J Sex Med; 2023 Feb; 20(2):161-169. PubMed ID: 36763929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Guzmán D; Guàrdia-Olmos J; Hinojosa-Calvo E; Herrera-Abarca JE
    J Psychiatr Res; 2009 Jun; 43(9):855-63. PubMed ID: 19128810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
    Herrera-Guzmán I; Herrera-Abarca JE; Gudayol-Ferré E; Herrera-Guzmán D; Gómez-Carbajal L; Peña-Olvira M; Villuendas-González E; Joan GO
    Psychiatry Res; 2010 May; 177(3):323-9. PubMed ID: 20385412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
    J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.